^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
OSE-279
i
Other names: OSE-279
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
OSE Immunotherapeutics
Drug class:
PD1 inhibitor
Related drugs:
1year
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
P1/2, N=24, Recruiting, OSE Immunotherapeutics
New P1/2 trial • Metastases
|
MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR
|
OSE-279
Share via
